After months of uncertainty, the Food and Drug Administration offered accelerated approval for an ultra-rare disease drug that had become a symbol of the fraught balancing act between upholding regulatory standards and accommodating desperate patients and their families.
The agency endorsed a treatment for Barth syndrome, a rare illness that afflicts about 150 people in the U.S. That decision comes after a protracted debate between the manufacturer, a small, privately held company called Stealth BioTherapeutics, and the FDA about how to generate enough of the right kind of data to prove the drug is effective in treating this tiny population of patients. The drug will be sold under the brand name Forzinity.
Over the past few years, the company endured a roller coaster as it attempted to convince the FDA to approve its drug, a saga that involved different agency divisions handling its application and pursuing various types of clinical studies to demonstrate that the medicine is effective. The uncertainty caused BioTherapeutics’ stock to dive and its key investor to take the company private.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Simply desire to say your article is as surprising The clearness in your post is simply excellent and i could assume you are an expert on this subject Fine with your permission let me to grab your feed to keep up to date with forthcoming post Thanks a million and please carry on the gratifying work